Table: q1_q4_2023_prescription_drug_wac_increases , manufacturer_name like L*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id	manufacturer_name	date_reported	ndc_number	drug_product_description	drug_category	drug_category_source	wac_effective_date	wac_increase_amount	wac_after_increase	patent_expiration_date	drug_source_type	unit_sales_volume_in_us	unit_sales_volume_non_public_indicator	cost_increase_factors	cost_increase_factors_non_public_indicator	change_improvement_description	change_improvement_non_public_indicator	acquisition_date	company_acquired_from	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	wac_at_acquisition	wac_year_prior_to_acquisition	year_drug_introduced_to_market	wac_at_intro_to_market	supporting_documents	general_comments
Rx0000083	Laboratoire HRA Pharma	06/30/2023	76336008060	Lysodren 500 mg tablets 100 count bottles	Brand	FDA	04/01/2023	116.42	1281.82	None	Single Source Drug	6000000	None	Pricing may change for reasons including: discovery of new uses or patient populations, need for clinical trial investment for such new uses or populations, improving quality and supply chain logistics, and other market factors	None	Pricing may change for reasons including: discovery of new uses or patient populations, need for clinical trial investment for such new uses or populations, improving quality and supply chain logistics, and other market factors	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000083	Laboratoire HRA Pharma	06/30/2023	76336045518	Metopirone 250 mg capsules 18 count bottles	Brand	FDA	04/01/2023	108.70	833.35	None	Single Source Drug	5000000	None	Pricing may change for reasons including: discovery of new uses or patient populations, need for clinical trial investment for such new uses or populations, improving quality and supply chain logistics, and other market factors	None	Pricing may change for reasons including: discovery of new uses or patient populations, need for clinical trial investment for such new uses or populations, improving quality and supply chain logistics, and other market factors	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000089	Lannett Company, Inc.	06/30/2023	00527150237	Dextroamphetamine-Amphetamine IR Tablets 10mg 100 Pack	Generic	FDA	04/04/2023	28.14	50.51	None	Non-innovator Multiple Source Drug	None	1	The change in WAC price reflects the increased cost to supply efficently to patients due to supply chain constraints, increased cost of storage, additional overhead, and marketing costs. Lannett and many drug manufacturers have seen increase in the cost of doing business due to shipping costs, high inflation rates impacting the cost of goods, the cost of hiring and keeping key resources, the supply chain disruptions of COVID and other factors has lead to the increase in prices in order to continue to provide life changing therapy to patients.	None	There was no change or improvement to the drug	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000089	Lannett Company, Inc.	06/30/2023	00527150337	Dextroamphetamine-Amphetamine IR Tablets 12.5mg 100 Pack	Generic	FDA	04/04/2023	28.14	50.51	None	Non-innovator Multiple Source Drug	None	1	The change in WAC price reflects the increased cost to supply efficently to patients due to supply chain constraints, increased cost of storage, additional overhead, and marketing costs. Lannett and many drug manufacturers have seen increase in the cost of doing business due to shipping costs, high inflation rates impacting the cost of goods, the cost of hiring and keeping key resources, the supply chain disruptions of COVID and other factors has lead to the increase in prices in order to continue to provide life changing therapy to patients.	None	There was no change or improvement to the drug	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000089	Lannett Company, Inc.	06/30/2023	00527150437	Dextroamphetamine-Amphetamine IR Tablets 15mg 100 Pack	Generic	FDA	04/04/2023	28.14	50.51	None	Non-innovator Multiple Source Drug	None	1	The change in WAC price reflects the increased cost to supply efficently to patients due to supply chain constraints, increased cost of storage, additional overhead, and marketing costs. Lannett and many drug manufacturers have seen increase in the cost of doing business due to shipping costs, high inflation rates impacting the cost of goods, the cost of hiring and keeping key resources, the supply chain disruptions of COVID and other factors has lead to the increase in prices in order to continue to provide life changing therapy to patients.	None	There was no change or improvement to the drug	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000089	Lannett Company, Inc.	06/30/2023	00527150537	Dextroamphetamine-Amphetamine IR Tablets 20mg 100 Pack	Generic	FDA	04/04/2023	28.14	50.51	None	Non-innovator Multiple Source Drug	None	1	The change in WAC price reflects the increased cost to supply efficently to patients due to supply chain constraints, increased cost of storage, additional overhead, and marketing costs. Lannett and many drug manufacturers have seen increase in the cost of doing business due to shipping costs, high inflation rates impacting the cost of goods, the cost of hiring and keeping key resources, the supply chain disruptions of COVID and other factors has lead to the increase in prices in order to continue to provide life changing therapy to patients.	None	There was no change or improvement to the drug	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000089	Lannett Company, Inc.	06/30/2023	00527150637	Dextroamphetamine-Amphetamine IR Tablets 30mg 100 Pack	Generic	FDA	04/04/2023	28.14	50.51	None	Non-innovator Multiple Source Drug	None	1	The change in WAC price reflects the increased cost to supply efficently to patients due to supply chain constraints, increased cost of storage, additional overhead, and marketing costs. Lannett and many drug manufacturers have seen increase in the cost of doing business due to shipping costs, high inflation rates impacting the cost of goods, the cost of hiring and keeping key resources, the supply chain disruptions of COVID and other factors has lead to the increase in prices in order to continue to provide life changing therapy to patients.	None	There was no change or improvement to the drug	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000089	Lannett Company, Inc.	06/30/2023	00527150037	Dextroamphetamine-Amphetamine IR Tablets 5mg 100 Pack	Generic	FDA	04/04/2023	28.14	50.51	None	Non-innovator Multiple Source Drug	None	1	The change in WAC price reflects the increased cost to supply efficently to patients due to supply chain constraints, increased cost of storage, additional overhead, and marketing costs. Lannett and many drug manufacturers have seen increase in the cost of doing business due to shipping costs, high inflation rates impacting the cost of goods, the cost of hiring and keeping key resources, the supply chain disruptions of COVID and other factors has lead to the increase in prices in order to continue to provide life changing therapy to patients.	None	There was no change or improvement to the drug	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000089	Lannett Company, Inc.	06/30/2023	00527150137	Dextroamphetamine-Amphetamine IR Tablets 7.5mg 100 Pack	Generic	FDA	04/04/2023	28.14	50.51	None	Non-innovator Multiple Source Drug	None	1	The change in WAC price reflects the increased cost to supply efficently to patients due to supply chain constraints, increased cost of storage, additional overhead, and marketing costs. Lannett and many drug manufacturers have seen increase in the cost of doing business due to shipping costs, high inflation rates impacting the cost of goods, the cost of hiring and keeping key resources, the supply chain disruptions of COVID and other factors has lead to the increase in prices in order to continue to provide life changing therapy to patients.	None	There was no change or improvement to the drug	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000089	Lannett Company, Inc.	12/31/2023	54838050280	Hydroxyzine HCl Syrup 10mg/5mL 473mg	Generic	FDA	10/16/2023	32.10	96.30	None	Non-innovator Multiple Source Drug	None	1	The change in WAC price reflects the increased cost to supply efficently to patients due to supply chain constraints, increased cost of storage, additional overhead, and marketing costs. Lannett and many drug manufacturers have seen increase in the cost of doing business due to shipping costs, high inflation rates impacting the cost of goods, the cost of hiring and keeping key resources, the supply chain disruptions of COVID and other factors has lead to the increase in prices in order to continue to provide life changing therapy to patients.	None	There was no change or improvement to the drug	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000089	Lannett Company, Inc.	03/31/2023	00527194866	levofloxacin Oral Solution 25mg/ mL bottle of 100mL	Generic	FDA	03/15/2023	145.16	256.82	None	Non-innovator Multiple Source Drug	None	1	The change in WAC price reflects the increased cost to supply efficiently to patients due to supply chain constraints, increased cost of storage, additional overhead, and marketing costs. Lannett and many drug manufacturers have seen increase in the cost of doing business due to shipping costs, high inflation rates impacting the cost of goods, the cost of hiring and keeping key resources, the supply chain disruptions of COVID and other factors has lead to the increase in prices in order to continue to provide life changing therapy to patients.	None	There was no change or improvement to the drug	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000089	Lannett Company, Inc.	03/31/2023	00527194868	levofloxacin Oral Solution 25mg/ mL bottle of 200mL	Generic	FDA	03/15/2023	290.32	513.64	None	Non-innovator Multiple Source Drug	None	1	The change in WAC price reflects the increased cost to supply efficiently to patients due to supply chain constraints, increased cost of storage, additional overhead, and marketing costs. Lannett and many drug manufacturers have seen increase in the cost of doing business due to shipping costs, high inflation rates impacting the cost of goods, the cost of hiring and keeping key resources, the supply chain disruptions of COVID and other factors has lead to the increase in prices in order to continue to provide life changing therapy to patients.	None	There was no change or improvement to the drug	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000089	Lannett Company, Inc.	03/31/2023	00527194870	levofloxacin Oral Solution 25mg/ mL bottle of 480mL	Generic	FDA	03/15/2023	689.78	1220.38	None	Non-innovator Multiple Source Drug	None	1	The change in WAC price reflects the increased cost to supply efficiently to patients due to supply chain constraints, increased cost of storage, additional overhead, and marketing costs. Lannett and many drug manufacturers have seen increase in the cost of doing business due to shipping costs, high inflation rates impacting the cost of goods, the cost of hiring and keeping key resources, the supply chain disruptions of COVID and other factors has lead to the increase in prices in order to continue to provide life changing therapy to patients.	None	There was no change or improvement to the drug	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000009	Lantheus Medical Imaging, Inc.	03/31/2023	11994001116	DEFINITY US 16Vial KIT. INJECTION, SUSPENSION, 6.52 mg/mL. 16 VIAL, GLASS in 1 CARTON (11994-011-16) > 1.5 mL in 1 VIAL, GLASS	Brand	FDA	01/01/2023	286.52	5061.88	05/04/2037	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000009	Lantheus Medical Imaging, Inc.	03/31/2023	11994001104	DEFINITY US 4Vial KIT. INJECTION, SUSPENSION, 6.52 mg/mL. 4 VIAL, GLASS in 1 CARTON (11994-011-04) > 1.5 mL in 1 VIAL, GLASS	Brand	FDA	01/01/2023	97.31	1313.68	05/04/2037	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000413	Leadiant Biosciences, Inc.	03/31/2023	54482002002	Cystaran (cysteamine ophthalmic solution) 0.44/15 ml bottle	Brand	FDA	01/09/2023	359.50	2105.00	None	Single Source Drug	None	1	Leadiant Biosciences, Inc. is a company exclusively focused on rare diseases. Leadiant employees work with rare dedication to provide therapies for patients with rare diseases. We partner with patient communities, physicians, and researchers worldwide to overcome challenges and be a resource of hope. We take decisions related to the pricing of our medicines very seriously. Given the complexities of manufacturing products for extremely small patient populations, and the difficulties of maintaining their availability to patients over time, Leadiant strives to find the right balance between ensuring that patients have access to the medicines they need while investing in new therapies for new groups of underserved populations. In light of recent inflation pressures, as well as our R&D expenditures into new technologies for patient benefit, we have adjusted the price of Cystaran as indicated in this report.	None	Not Applicable.	None	None	None	None	None	None	None	None	None	None	None	With regard to Cystaran, our company transitioned to a new manufacturer and during the transition timeframe, we invested in an alternate bottle design to improve the patient experience. The new bottle design was assigned a new NDC number and was introduced to the market in 2022. WAC prices for earlier years relate to the predecessor NDC number 54482-0020-01, which utilized the old bottle design. The WAC prices under the previous NDC are: 3. WAC Effective Date: 1/1/2021, WAC Increase Amt: $42.14, WAC After Increase: $1,662.75                                                                                                                4. WAC Effective Date: 1/1/2020, WAC Increase Amt: $40.61, WAC After Increase: $1,620.61 5. WAC Effective Date: 1/1/2019, WAC Increase Amt: $46.00, WAC After Increase: $1,580.00
Rx0000413	Leadiant Biosciences, Inc.	03/31/2023	54482005401	Matulane (procarbazine hydrochloride) 50mg Capsules (100 p/bottle)	Brand	FDA	01/03/2023	957.53	12926.64	None	Single Source Drug	None	1	Our pricing has been adjusted substantially in consideration of increased manufacturing and supply costs, increased regulatory maintenance costs, and decreasing volumes that make it incrementally onerous for Leadiant to keep Matulane in the market and available to patients.	None	Not Applicable.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000025	Lundbeck LLC	03/31/2023	67386082019	Northera 100mg. 90 Capsules	Brand	FDA	01/02/2023	168.16	3531.38	None	Innovator Multiple Source Drug	None	1	"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies."	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.
Rx0000025	Lundbeck LLC	03/31/2023	67386082119	Northera 200mg. 90 Capsules	Brand	FDA	01/02/2023	336.32	7062.73	None	Innovator Multiple Source Drug	None	1	"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies."	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.
Rx0000025	Lundbeck LLC	03/31/2023	67386082219	Northera 300mg. 90 Capsules	Brand	FDA	01/02/2023	504.48	10594.12	None	Innovator Multiple Source Drug	None	1	"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies."	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.
Rx0000025	Lundbeck LLC	03/31/2023	67386031401	Onfi 10mg. 100 Tablets	Brand	FDA	01/02/2023	215.28	2748.02	None	Innovator Multiple Source Drug	None	1	"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies."	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.
Rx0000025	Lundbeck LLC	03/31/2023	67386031501	Onfi 20mg. 100 Tablets	Brand	FDA	01/02/2023	430.56	5495.98	None	Innovator Multiple Source Drug	None	1	"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies."	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.
Rx0000025	Lundbeck LLC	03/31/2023	67386031321	Onfi Oral Suspension 2.5mg/mL 120mL Bottle	Brand	FDA	01/02/2023	113.11	1443.83	None	Innovator Multiple Source Drug	None	1	"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies."	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.
Rx0000025	Lundbeck LLC	03/31/2023	67386011101	Sabril 500mg. 100 Tablets	Brand	FDA	01/02/2023	961.05	20182.05	None	Innovator Multiple Source Drug	None	1	"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies."	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.
Rx0000025	Lundbeck LLC	03/31/2023	67386021165	Sabril 500mg. 50 Packets 500mg. each	Brand	FDA	01/02/2023	480.53	10091.04	None	Innovator Multiple Source Drug	None	1	"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies."	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.
Rx0000025	Lundbeck LLC	03/31/2023	67386042101	Xenazine 12.5mg. 112 Tablets	Brand	FDA	01/02/2023	927.47	19476.92	None	Innovator Multiple Source Drug	None	1	"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies."	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.
Rx0000025	Lundbeck LLC	09/30/2023	67386042101	Xenazine 12.5mg. 112 Tablets	Brand	FDA	07/01/2023	779.08	20256.00	None	Innovator Multiple Source Drug	None	1	"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies."	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.
Rx0000025	Lundbeck LLC	03/31/2023	67386042201	Xenazine 25.0mg. 112 Tablets	Brand	FDA	01/02/2023	1854.95	38953.86	None	Innovator Multiple Source Drug	None	1	"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies."	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.
Rx0000025	Lundbeck LLC	09/30/2023	67386042201	Xenazine 25.0mg. 112 Tablets	Brand	FDA	07/01/2023	1558.15	40512.01	None	Innovator Multiple Source Drug	None	1	"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies."	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.